Dulaglutide for peritoneal dialysis in diabetic kidney disease

Phase 1

• Conditions: Diabetes and peritoneal dialysis; Nutritional, Metabolic, Endocrine

• Registration Number: ISRCTN13300160
• Lead Sponsor: Chang Gung Memorial Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-10-26
• Last Update Posted: 7 November 2022
• Study Completion: 2026-12-31

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 75

Inclusion Criteria

1. CKD with a clinical cause of diabetes mellitus
2. Age is = 20 and= 75 years
3. The subject had been receiving peritoneal dialysis for more than 3 months.
4. The subject treat with or without OHAs or insulin treatment
5. The subject doesn’t treated with GLP-1 analogue
6. The subject is able and willing to return for required follow-up visits and examinations.

Exclusion Criteria

1. Female participants who are pregnant or breastfeeding
2. Participants who have any of the following medical conditions:
2.1. Chronic inflammatory or autoimmune diseases
2.2. Viral Hepatitis B or C liver infection, liver cirrhosis, or significant liver disease
2.3. CKD from causes other than diabetes
2.4. Cancer (malignancy)
2.5. Febrile illnesses
2.6. Age is < 20 or >75 years
2.7. The subject has a life expectancy of less than one years.
2.8. The subject has allergic reaction to any GLP-1 analogues.
2.9. HIV infection- the virus that causes AIDS
2.10. The subject is deemed by study physicians to be unsuitable for enrollment.
2.11. The subject is currently enrolled in another investigational study or registry that would directly/indirectly interfere with the current study.
2.12. The subject is unable or unwilling to return for required follow-up and examination.

Study & Design

• Study Type: Interventional
• Study Design: Not specified